Modified VEGF proteins that inhibit VEGF-mediated activation or proliferationof endothelial cells are disclosed. The analogs may be used to inhibit VEGF-mediatedactivation of endothelial cells in angiogenesis-associated diseases suchas cancer, inflammatory diseases, eye diseases, and skin disorders.